March 2026
1. RUAN J, Gao C, Wang R, Hu B, et al
   A novel dual-effect bimodal chip cancer research platform: Chips system interconnected vascularized tumor organoids culture with real-time exploration and detection from bench to bedside.
   Cancer Lett. 2026;640:218110.
   

   >> Share

   
   February 2026
2. HE G, Qu X, Ding Z, Liang J, et al
   IGSF3 binds to TNFR2 on Treg to facilitate immunosuppression in cervical cancer.
   Cancer Lett. 2026 Feb 12:218307. doi: 10.1016/j.canlet.2026.218307.
   

   >> Share

   
   January 2026
3. ZHAO Q, Yao Y, Liang T, Chen M, et al
   Neutrophil Extracellular Traps Enhance Platinum Resistance in Ovarian Cancer via SHP-1 Activation.
   Cancer Lett. 2026 Jan 29:218288. doi: 10.1016/j.canlet.2026.218288.
   

   >> Share

   
   
4. YUAN M, Hong Y, Feng Y, Sun J, et al
   Cervical Cancer Incidence and Mortality Trends in China: The role of Screening.
   Cancer Lett. 2026 Jan 27:218286. doi: 10.1016/j.canlet.2026.218286.
   

   >> Share

   
   
5. LIU B, Cai Z, Sun H, Liu Z, et al
   A Pt (IV)/losartan/immunotherapy Co-delivery thermosensitive gel synergizes STING activation and cancer-associated fibroblast inhibition for ovarian cancer chemoimmunotherapy.
   Cancer Lett. 2026;639:218242.
   

   >> Share

   
   
6. LIAO B, Chen L, Ruan J, Wang R, et al
   Microbiome and gartynecologic cancer.
   Cancer Lett. 2026;636:217940.
   

   >> Share

   
   December 2025
7. DONG K, Cai M, Jia X, Qu H, et al
   A novel phenomena: extrachromosomal DNA harboring highly amplified and overexpressed genes undergo intercellular transmission in ovarian cancer cells.
   Cancer Lett. 2025;639:218231.
   

   >> Share

   
   
8. XU H, Zeng S, Wang M, Wang Y, et al
   Cytoplasmic SIRT1 enhances the stemness of polyploid giant cancer cells by promoting beta-catenin protein stability and nuclear accumulation in ovarian carcinoma upon neoadjuvant chemotherapy.
   Cancer Lett. 2025 Dec 1:218193. doi: 10.1016/j.canlet.2025.218193.
   

   >> Share

   
   November 2025
9. NI Y, Zhou X, Tang Y, Ren W, et al
   SB225002 Enhances Radiosensitivity in Cervical Cancer via Direct Neutrophil Inhibition and Tumor Cell Suppression.
   Cancer Lett. 2025 Nov 17:218153. doi: 10.1016/j.canlet.2025.218153.
   

   >> Share

   
   
10. SAORIN G, Mauceri M, Caligiuri I, Kamensek U, et al
    Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer.
    Cancer Lett. 2025;637:218128.
    

    >> Share

    
    October 2025
11. EL BABA R, Haidar Ahmad S, Vanhulle C, Vreux L, et al
    Formation of polyploid giant cancer cells and the transformative role of human cytomegalovirus IE1 protein.
    Cancer Lett. 2025;630:217824.
    

    >> Share

    
    July 2025
12. YANG X, Li C, Cheng Y, Qin S, et al
    YY1-Glycolytic Axis Promotes High Glucose-induced Cancer Stemness in Endometrial Cancer: A Multi-Omics Guided Therapeutic Strategy.
    Cancer Lett. 2025 Jul 23:217936. doi: 10.1016/j.canlet.2025.217936.
    

    >> Share

    
    
13. LI J, Shi J, Ding J, Qu W, et al
    Metabolic gatekeeper ACAD9 coordinates linoleic acid metabolism and redox homeostasis via mitochondrial complex I to drive ovarian cancer progression.
    Cancer Lett. 2025;630:217903.
    

    >> Share

    
    
14. DOGRA S, Elayapillai SP, Qu D, Pitts K, et al
    Corrigendum to "Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer" [Cancer Lett. 2023 Dec 1;578:216437].
    Cancer Lett. 2025 Jul 2:217889. doi: 10.1016/j.canlet.2025.217889.
    

    >> Share

    
    June 2025
15. AO K, Yin M, Lyu X, Xiao Y, et al
    Corrigendum to "METTL3-mediated HSPA9 m6A modification promotes malignant transformation and inhibits cellular senescence by regulating exosomal mortalin protein in cervical cancer" [Cancer Lett. 587 (2024) 216658].
    Cancer Lett. 2025 Jun 3:217827. doi: 10.1016/j.canlet.2025.217827.
    

    >> Share

    
    May 2025
16. GONG Y, Zhang W, Wang X, Zheng S, et al
    A previously uncharacterized role of TAp73 in ferroptosis by modulating oxidative homeostasis in cervical cancer.
    Cancer Lett. 2025;627:217815.
    

    >> Share

    
    April 2025
17. DURAKI D, Jabeen M, Mao C, Wang L, et al
    A Necrosis Inducer Promotes an Immunogenic Response and Destroys Ovarian Cancers in Mouse Xenografts and Patient Ascites Organoids.
    Cancer Lett. 2025 Apr 29:217738. doi: 10.1016/j.canlet.2025.217738.
    

    >> Share

    
    March 2025
18. LI H, Chatla S, Liu X, Tian Z, et al
    ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
    Cancer Lett. 2025;613:217505.
    

    >> Share

    
    February 2025
19. WANG Q, Liu W, Fan Y, Liu S, et al
    Enhancing the Antitumor Effect of MUC16 CART Cells in Ovarian Cancer: The Potential of Oncolytic Adenovirus.
    Cancer Lett. 2025 Feb 25:217588. doi: 10.1016/j.canlet.2025.217588.
    

    >> Share

    
    
20. TAMURA T, Nagai S, Masuda K, Imaeda K, et al
    mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer.
    Cancer Lett. 2025 Feb 17:217565. doi: 10.1016/j.canlet.2025.217565.
    

    >> Share

    
    
21. GUO M, He M, Dang Y, Lei L, et al
    Predictors of para-aortic lymph node metastasis based on pathological diagnosis via surgical staging in patients with locally advanced cervical cancer: A multicenter study.
    Cancer Lett. 2025 Feb 15:217545. doi: 10.1016/j.canlet.2025.217545.
    

    >> Share

    
    
22. LI X, Yang X, Lin S, Cong H, et al
    Perineural Invasion in Cervical Cancer.
    Cancer Lett. 2025 Feb 14:217561. doi: 10.1016/j.canlet.2025.217561.
    

    >> Share

    
    December 2024
23. LOMELI N, Pearre DC, Lepe J, Argueta DA, et al
    N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model.
    Cancer Lett. 2024 Dec 18:217405. doi: 10.1016/j.canlet.2024.217405.
    

    >> Share

    
    November 2024
24. FIELD NR, Dickson KA, Nassif NT, Marsh DJ, et al
    SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling.
    Cancer Lett. 2024;605:217282.
    

    >> Share

    
    
25. BHOWMIK AD, Shaw P, Gopinatha Pillai MS, Rao G, et al
    Evolving Landscape of Detection and Targeting miRNA/Epigenetics for Therapeutic Strategies in Ovarian Cancer.
    Cancer Lett. 2024 Nov 28:217357. doi: 10.1016/j.canlet.2024.217357.
    

    >> Share

    
    October 2024
26. NING Y, Chen Y, Tian T, Gao X, et al
    S100A7 Orchestrates Neutrophil Chemotaxis and Drives Neutrophil Extracellular Traps (NETs) Formation to Facilitate Lymph Node Metastasis in Cervical Cancer Patients.
    Cancer Lett. 2024 Oct 7:217288. doi: 10.1016/j.canlet.2024.217288.
    

    >> Share

    
    September 2024
27. LEWIS F, Beirne J, Henderson B, Norris L, et al
    Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma.
    Cancer Lett. 2024 Sep 26:217279. doi: 10.1016/j.canlet.2024.217279.
    

    >> Share

    
    August 2024
28. WU H, Sun C, Cao W, Teng Q, et al
    Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer.
    Cancer Lett. 2024;602:217192.
    

    >> Share

    
    July 2024
29. JAISWAL SK, Fedkenheuer K, Khamar R, Tan H, et al
    The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer.
    Cancer Lett. 2024 Jul 22:217129. doi: 10.1016/j.canlet.2024.217129.
    

    >> Share

    
    
30. XU J, Lu W, Wei X, Zhang B, et al
    Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
    Cancer Lett. 2024;593:216928.
    

    >> Share

    
    June 2024
31. FENG X, Ji Z, Fan X, Kong Y, et al
    ASS1 Enhances Anoikis Resistance via AMPK/CPT1A-mediated Fatty Acid Metabolism in Ovarian Cancer.
    Cancer Lett. 2024 Jun 22:217082. doi: 10.1016/j.canlet.2024.217082.
    

    >> Share

    
    
32. MENG H, Miao H, Zhang Y, Chen T, et al
    YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.
    Cancer Lett. 2024 Jun 14:217064. doi: 10.1016/j.canlet.2024.217064.
    

    >> Share

    
    
33. YU Y, Lyu C, Li X, Yang L, et al
    Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis.
    Cancer Lett. 2024;596:217022.
    

    >> Share

    
    April 2024
34. HA JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, et al
    Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer.
    Cancer Lett. 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891.
    

    >> Share

    
    
35. KAUR P, Shankar E, Gupta S
    EZH2-mediated development of therapeutic resistance in cancer.
    Cancer Lett. 2024;586:216706.
    

    >> Share

    
    March 2024
36. PONGRATANAKUL P, Bremmer F, Pauls S, Poschmann G, et al
    Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.
    Cancer Lett. 2024;585:216673.
    

    >> Share

    
    
37. CAO C, Xu Q, Zhu Z, Xu M, et al
    Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer.
    Cancer Lett. 2024 Mar 10:216809. doi: 10.1016/j.canlet.2024.216809.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share